![A lung cancer precision medicine trial: Lung-MAP](/sites/default/files/styles/news_recent/public/news/2022-03/LungMap.Twitter%201.png?itok=LrtgtovT)
Mar 31, 2022
The spring 2022 newsletter for Lung-MAP participating sites is now available.
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-03/FrontLineHeader.web-sized_2.png?itok=C4dvAz7D)
Mar 25, 2022
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-03/FrontLineHeader.web-sized.png?itok=u2_OBuN8)
Mar 4, 2022
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2022-02/FrontLineHeader.web-sized_1.png?itok=IYu34yFg)
Feb 18, 2022
![S1314 at GU ASCO](/sites/default/files/styles/news_recent/public/news/2022-02/press-release-web-graphic-Flaig-S1314-GU-ASCO-2022_0.png?itok=9rrfByfW)
Feb 15, 2022
Survival data from the first prospective, randomized biomarker validation trial in muscle-invasive bladder cancer presented at GU ASCO
![Sex differences in risk of SAEs](/sites/default/files/styles/news_recent/public/news/2022-02/press-release-web-graphic-Unger-sex-diffs-SAEs.png?itok=sz1ThvmM)
Feb 14, 2022
Higher toxicity risk for women was known for chemotherapy, now also identified for immunotherapy and targeted therapy